Need a Reliable Peptide Supplier? Click HERE!!!SponsoredVisit ↗
Danuglipron and BAC Water Mix

Danuglipron Reconstitution Calculator

Enter the amount you want to measure. The vial buttons will highlight which vial strengths create cleaner syringe-unit measurements.

What amount do you need?

Type the target amount, then choose mg or mcg. Example: 2mg or 500mcg.

Work the dose out from body weight

Syringe size:
Possible vial strengths:
Best Match Good Match Usable Harder to Measure

Example Danuglipron Titration Schedule

ParameterDetails
Phase 2b doses40–200 mg oral twice daily
Cycle12–32 weeks (trials)

Discontinued April 2025: one case of potential drug-induced liver injury (resolved on discontinuation). Historical data only — no supply exists.

Possible vial strengths:

What Is It?

Danuglipron

Oral small-molecule GLP-1 receptor agonist.

Bacteriostatic Water

Sterile water containing a bacteriostatic preservative, commonly used when preparing multi-use research vials.

How To Mix Danuglipron

1
Clean

Use alcohol swabs to clean the tops of both vials.

2
Draw BAC Water

Draw the selected amount of bacteriostatic water.

3
Inject Slowly

Add the liquid slowly down the side of the vial.

4
Swirl Gently

Do not shake. Swirl gently until dissolved.

5
Store Properly

Store as directed and protect from heat and light.

Best Practices & Common Mistakes

Best Practices

  • Use sterile technique.
  • Protect from light and heat.
  • Store refrigerated when appropriate.
  • Use clean syringe-unit math before measuring.

Common Mistakes

  • Confusing milligrams with milliliters.
  • Choosing an option with awkward decimal units.
  • Using too little liquid for very small measurements.
  • Shaking the vial aggressively.

Danuglipron Storage & Handling

Lyophilized Powder: −20°C (−4°F) for long-term storage (up to 24 months). Refrigeration 2–8°C (36–46°F) for short-term use (up to ~3 months). Original sealed vial in the freezer is safest.
Reconstituted Solution: 2–8°C (36–46°F), use within ~7–14 days. Keep sealed, avoid light, and do not repeat freeze-thaw cycles.

Frequently Asked Questions

“Anuglipron” is most likely a misspelling of danuglipron, Pfizer’s investigational oral GLP-1 receptor agonist. It was studied as a small-molecule obesity and diabetes drug candidate, not as a peptide vial intended for bacteriostatic-water reconstitution.
Danuglipron is not a peptide; it is a synthetic small molecule with a listed molecular weight of about 555.6 g/mol. If a calculator page includes danuglipron, it should frame the math as research concentration calculation only, not as a peptide injection or human-use protocol.
Pfizer discontinued danuglipron development in 2025 after a potential drug-induced liver injury signal appeared in one study participant during dose optimization. The participant had no symptoms, liver enzymes returned to normal after stopping the compound, and Pfizer said it would not continue the program.
Earlier Phase 2b data showed weight-loss signals, but tolerability was a major limitation. Pfizer reported dose-related gastrointestinal side effects such as nausea, vomiting, and diarrhea, and the twice-daily version did not move forward into Phase 3.
For research math only, concentration is calculated by dividing compound amount by final liquid volume. For example, if 25 mg of danuglipron reference material were dissolved to a final volume of 8 mL, the concentration would be 3.125 mg/mL, so a 5 mg research amount would equal 1.60 mL; this is not an injection guide or dosing recommendation.
Practical takeaway: If your goal involves weight management, metabolic health, recovery, physical performance, cognitive function, appearance, or general well-being, discuss it with a licensed healthcare professional. They can help you evaluate approved, evidence-based options rather than relying on an unapproved or investigational compound. This calculator is intended only for transparent research-reference calculations and does not determine an appropriate amount, recommend use, or replace professional medical guidance.

About the author

Maria Hrabina is a pharmacist and scientific reviewer with a strong interest in peptide science, pharmacology, and emerging therapeutic compounds.

Her work focuses on understanding how peptide-based compounds interact with biological signaling pathways and how they are being investigated across areas such as metabolic health, dermatology, recovery, regenerative research, and pharmaceutical development.

Maria follows research on a broad range of peptides, from compounds used in approved medicines to experimental molecules still being evaluated in laboratory, preclinical, and clinical studies.

Her approach combines scientific curiosity with critical evaluation of evidence. She believes promising mechanisms and early research deserve attention, but should not be presented as established clinical benefits until they are supported by adequate human data.

Her areas of focus include scientific literature review, mechanisms of action, pharmacology, pharmacokinetics, safety, pharmaceutical formulation, and the overall quality of evidence behind peptide-based compounds.

She is particularly interested in the process of translating an experimental molecule into a reliable pharmaceutical product — including compound characterization, purity, stability, formulation, dose selection, safety assessment, and controlled clinical trials.

Maria believes peptide science has significant long-term potential, but that its progress depends on rigorous research, high manufacturing standards, transparent safety data, and responsible scientific communication.

Through her writing, she aims to help readers understand both sides of peptide research: what makes these compounds scientifically promising and what questions remain before their potential can be considered clinically established.

Areas of interest: Peptide Science · Therapeutic Peptides · Peptide Pharmacology · Metabolic Peptides · Cosmetic Peptides · Drug Development · Pharmacokinetics · Drug Safety · Pharmaceutical Formulation · Emerging Therapies · Evidence-Based Medicine

Important: This tool is for informational and research-reference purposes only. Not intended for human or veterinary use.
← All peptides